<DOC>
	<DOCNO>NCT02699645</DOCNO>
	<brief_summary>An investigator initiate conduct , multicentre , international , double-blinded , placebo-controlled , parallel-group , randomise control trial determine effect fix low-dose combination blood pressure lower pill ( `` Triple Pill '' ) top standard care blood pressure control time first occurrence recurrent stroke patient history acute intracerebral haemorrhage ( TRIDENT ) .</brief_summary>
	<brief_title>Triple Therapy Prevention Recurrent Intracerebral Disease EveNts Trial</brief_title>
	<detailed_description>Acute intracerebral haemorrhage ( ICH ) serious least treatable form stroke , account least 10 % 20 million new stroke occur globally year . Survivors ICH high risk recurrent ICH serious cardiovascular event . While strong evidence risk reduce lower blood pressure ( BP ) patient ICH , many patient ICH receive blood pressure lower long-term unless blood pressure level particularly high , many receive BP combination therapy . The aim study assess safety efficacy combination fix low-dose generic BP lowering agent `` Triple Pill '' strategy top standard care prevention recurrent stroke patient history ICH high normal low grade hypertension large-scale , international , double-blind , placebo-controlled , randomise control trial .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Indapamide</mesh_term>
	<criteria>Adults ( â‰¥18 year ) history 6 month symptom onset acute stroke cause primary ICH confirm image Clinically stable , judged investigator Two rest SBP level measure 5 minute apart range 130160mmHg record seat position . ( Patients high SBP include consider attend clinician management consistent local standard clinical practice ) Geographical proximity recruit hospital and/or followup medical clinic site allow ready access inperson clinic visit followup Provision write informed consent Taking angiotensin convert enzyme inhibitor switch follow alternative : telmisartan 20 40mg , amlodipine 2.5 5mg , indapamide 1.25 2.5mg , equivalent class ( Angiotensin II Receptor Blocker ( ARB ) , Calcium Channel Blocker ( CCB ) thiazidelike diuretic ) , betablocker Contraindication study medication , context currently prescribe BP lower medication Unable complete study procedure and/or followup Females child bear age capability , pregnant breastfeeding , use adequate birth control Emergent side effect prevent longterm treatment 14 week active runin phase open treatment Any condition opinion responsible physician investigator render patient unsuitable study ( e.g . severe disability [ ie modify Rankin Score 45 ] significant memory behavioural disorder )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>